Close



Jan 3, 2024 01:16PM
Oct 18, 2023 08:26AM
Sep 25, 2023 09:53AM
Sep 25, 2023 07:58AM
Dec 19, 2022 08:19AM
May 27, 2022 09:00AM
May 3, 2022 07:00AM Blueprint Medicines Reports First Quarter 2022 Results
Jul 12, 2021 04:41PM
Jul 12, 2021 10:52AM
Mar 16, 2021 07:49AM
Dec 14, 2020 09:28AM
Nov 12, 2020 09:37AM
Aug 12, 2020 09:52AM
Jul 27, 2020 01:17PM U.S. drugmaker earnings heat up this week with spotlight on vaccine news
Jun 7, 2020 04:21AM
Dec 11, 2018 08:07AM
Nov 13, 2018 05:52AM
Aug 16, 2018 05:35AM
Mar 19, 2018 04:56AM
Apr 10, 2017 07:46AM
Nov 9, 2016 12:03PM Complete Donald Trump Stock Impact Guide
Sep 12, 2016 06:42AM
Aug 5, 2016 10:43AM
Jul 17, 2016 10:32PM
Mar 15, 2016 06:56AM
Feb 4, 2016 02:27AM
Dec 17, 2015 09:11AM
Dec 17, 2015 02:44AM AstraZeneca buys most of Acerta for $4 billion to add cancer drug
Nov 13, 2015 12:01PM
Dec 4, 2014 10:22AM
Nov 26, 2014 06:44AM
Apr 22, 2014 10:38AM
Apr 21, 2014 09:33AM
Jan 9, 2014 07:35AM
Oct 11, 2013 07:58AM Jefferies Downgrades AstraZeneca (AZN) to Underperform
Jun 5, 2013 02:39PM
May 28, 2013 09:32AM
May 28, 2013 08:34AM
Apr 10, 2013 08:30AM
Aug 20, 2012 09:31AM
Aug 17, 2012 05:08PM
Jul 13, 2012 08:32AM Jefferies on Pharmaceuticals: Global Pharmaceuticals Q2'12 Earnings Preview; Where is it Safe to Hide?
Jun 5, 2012 07:38AM
Dec 20, 2011 02:13PM
Oct 19, 2011 12:14PM
Aug 15, 2011 04:52PM
Jun 2, 2011 10:34AM
Jun 2, 2011 07:21AM
Mar 10, 2011 07:59AM Jefferies Cuts Price Target on POZEN Inc. (POZN) by 28.5%, Major Patent Risk
Jan 11, 2011 09:06AM

56,417 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All